Skip to content
    ELV
    Earnings call· Jun 2025(Q2 FY25)

    Elevance Health Q2 FY25 earnings call ELV

    Jul 17, 2025 Source

    Executive summary

    Elevance Health Q2 FY25 — Revised Full-Year Outlook Amid ACA and Medicaid Cost Pressures

    Elevance Health revised its full-year 2025 adjusted EPS guidance to approximately $30, acknowledging persistent elevated medical cost trends in its ACA and Medicaid businesses. The company is taking decisive actions to stabilize trends, align pricing, and strengthen its operational foundation for long-term sustainability, focusing on areas within its control. Despite the challenges, the Carelon platform continues to drive significant growth, and management remains committed to transparency and execution.

    Highlights

    5

    • Adjusted EPS consistent with expectations for Q2 FY25.

    • Carelon Rx operating revenue grew over 20% year-over-year, gaining traction with larger clients.

    • Carelon Services delivered greater than 50% growth in revenue and operating gain through expansion of risk-based relationships and CareBridge integration.

    • Adjusted operating expense ratio improved 140 basis points year-over-year to 10.0%.

    • Medicare Advantage cost trends remained in line with expectations, targeting stable margins for the year.

    Concerns

    5

    • Full-year 2025 adjusted EPS guidance revised down to approximately $30 from previous outlook.

    • Elevated medical cost trends in ACA and slower-than-expected Medicaid rate alignment are expected to persist in H2 FY25.

    • Consolidated benefit expense ratio increased 260 basis points year-over-year to 88.9%.

    • Medicaid cost trend deceleration was more modest than initially expected, leading to a prolonged margin recovery period.

    • ACA risk pool acuity and morbidity have risen materially, driven by Medicaid redeterminations and lower effectuation rates, contributing to 70% of the impact.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2025 Adjusted EPS
    approximately $30
    high materiality
    High
    Full-year 2025 Operating Cash Flow
    approximately $6 billion
    medium materiality
    High
    Full-year 2025 Benefit Expense Ratio
    approximately 90%
    high materiality
    High
    Full-year Diluted Weighted Average Share Count
    225 million to 226 million
    low materiality
    High
    Medicaid Margins
    show year-over-year improvement in the back half, remain positive for the full year, albeit below our long-term targets
    medium materiality
    High
    ACA Operating Margin
    decline year-over-year in the high single-digit percent range
    high materiality
    High
    Q3 vs Q4 Earnings Seasonality
    slightly more earnings to be realized in the third quarter relative to the fourth quarter
    low materiality
    High
    Capital Allocation Algorithm
    deploying about 50% of free cash flow towards M&A, organic reinvestment... with the other 50% being returned to shareholders, including 30% for share repurchases and about 20% for dividends
    medium materiality
    High

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Carelon Rx
    Operating revenue grew over 20% year-over-year, gaining traction with larger clients and scaling specialty pharmacy assets. Profitability was impacted by ongoing initiatives around accelerating growth as the company expands upmarket.
    		—over 20%——
    Carelon Services
    Delivered greater than 50% growth in revenue and operating gain through expansion of risk-based relationships and the integration of CareBridge. Margins came in within expectations, slightly down from last year due to CareBridge and increased risk arrangements.
    		—greater than 50%—greater than 50% operating gain
    ACA
    Operating margin is expected to decline year-over-year in the high single-digit percent range due to a broad recalibration of the market, increased morbidity, and elevated medical cost trends.
    		———expected to decline year-over-year in the high single-digit percent range
    Medicaid
    Cost trend decelerated more modestly than expected, leading to a prolonged margin recovery period. Margins are still expected to show year-over-year improvement in the back half and remain positive for the full year, though below long-term targets.
    		———expected to show year-over-year improvement in H2, remain positive for full year, albeit below long-term targets
    Medicare Advantage
    Cost trends remained in line with expectations, with Part D seasonality progressing as anticipated. The company continues to target stable margins for the year.
    		———stable margins targeted
    Commercial (Large Group)
    The large group commercial business continues to show strong consistent margin performance. The market is hardening in terms of pricing, and retention on mid-year renewals (July cohort) was comfortable.
    		———strong consistent margin performance expected

    Operational metrics

    13
    Adjusted EPS
    $8.84
    Q2 FY25

    Consistent with expectations.

    Operating Revenue
    $49.4 billion14% year-over-year increase
    Q2 FY25

    Principally reflecting higher premium yields and recently completed acquisitions in home health and specialty pharmacy.

    Adjusted Operating Expense Ratio
    10.0%improved 140 basis points year-over-year
    Q2 FY25

    Prioritizing strategic investments in innovative care models, AI, and pharmacy services.

    Debt-to-Capital Ratio
    40.8%
    Q2 FY25 end

    Preserving flexibility for strategic investments and opportunistic capital deployment.

    Share Repurchases
    $2 billion
    YTD

    Returned to investors year-to-date.

    Share Repurchases
    $380 million
    Q2 FY25

    Repurchased in the second quarter, with adjusted pacing to ensure flexibility.

    ACA Risk Pool Acuity/Morbidity Impact
    70%
    Q2 FY25

    Contribution to total impact on medical trends, driven by Medicaid migration and lower effectuation rates.

    ACA Utilization/Coding Impact
    30%
    Q2 FY25

    Contribution to total impact on medical trends, from utilization (ER, behavioral health, specialty pharmacy) and aggressive coding/IDR misuse.

    Medicaid Cost Trend Drivers
    1/3 acuity, 2/3 utilization and codingdifferent from 2024 (60% acuity, 40% utilization)
    FY25 forecast

    Reflects that most redetermination-related acuity impact has been absorbed, while elevated utilization is now coming through.

    Benefit Expense in Downside Risk Arrangements
    over 1/3
    current

    Expanding value-based care portfolio, particularly in behavioral health and oncology.

    Electronic Prior Authorization Processing
    over half
    current

    Streamlined processes with electronic requests now processed in real-time.

    ER Utilization (ACA vs Commercial)
    nearly 2xACA members vs commercial group members
    Q2 FY25

    ACA members in the 2024-'25 cohort utilizing the emergency room at nearly twice the level of commercial group members.

    Prior Period Development
    $40 million
    Q2 FY25

    Approximately $40 million for the quarter, with nothing of particular note to call out.

    Industry KPIs

    8
    MetricValueDetails
    Utilization trendsElevated
    Stars rate environmentDisciplined approach
    Medical loss care ratio88.9% (Q2 FY25); ~90% (FY25 guidance)%
    Pharmacy scripts specialtyOver 20% growth%
    Membership covered lives by line45.6 millionmembers
    Segment revenue operating incomeCarelon Rx: >20% growth; Carelon Services: >50% growth%
    Adjusted EPS EBITDA leverage guidance$8.84 (Q2 FY25); ~$30 (FY25 guidance)USD
    Medical cost trend vs pricing assumptionElevated

    Deals & partnerships

    1
    Multiple (unnamed)Acquisitions in home health and specialty pharmacy

    Recently completed acquisitions in home health and specialty pharmacy, with a focus in 2025 on integration and scaling.

    Risks & headwinds

    6
    Elevated medical cost trends (ACA & Medicaid)H2 FY25 and beyond

    FY25 adjusted EPS guidance revised to ~$30; benefit expense ratio ~90%; 260 bps YoY increase in benefit expense ratio.

    Mitigation: Disciplined pricing for 2026, intensifying care management programs, selective provider contract actions, proactive engagement with states for rate alignment.

    ACA risk pool deteriorationFY25 and into 2026

    ACA operating margin expected to decline in high single-digit percent range YoY; 70% of total impact on medical trends from risk pool acuity/morbidity.

    Mitigation: 2026 rate filings capture higher market acuity and potential further deterioration from subsidy expiration; CMS marketplace integrity and affordability rule provisions (e.g., elimination of monthly special enrollment periods, strengthened preenrollment verification of income).

    Slower Medicaid rate alignmentNext couple of rate cycles

    Prolonged margin recovery period; Medicaid margins positive for FY25 but below long-term targets.

    Mitigation: Proactive engagement with state partners, sharing data to support rate adjustments, expecting normalization over a couple of rate cycles.

    Misuse of Independent Dispute Resolution (IDR) processOngoing

    Out-of-network providers submitting thousands of disputes, payment requests up to 21x bill charges.

    Mitigation: Legal suit filed against billing companies, payment integrity processes, using technology to identify aberrant patterns.

    Policy uncertainties (ACA subsidies, Medicaid work requirements)2026 and beyond

    Potential near-term enrollment pressures and risk pool shifts.

    Mitigation: Monitoring implications of budget reconciliation bill; strong partnerships with states; leveraging capabilities to manage changes; experience in states with work requirements (Indiana, Georgia).

    Provider AI-enabled coding tools for revenue inflationOngoing

    Isolated pockets where hospitals use AI to increase document acuity and unit costs, contributing to outlier claims and higher allowed amounts.

    Mitigation: Flagging and tracking these practices; payment integrity processes; differentiating between responsible innovation and revenue inflation; using technology to identify aberrant patterns and taking swift action.

    What to watch in Q3 FY25

    5

    ACA margin recovery

    2026
    CurrentExpected to decline high single-digit percent range YoY in FY25
    TargetImprovement towards long-term sustainability

    Why it matters

    Critical for the profitability of the ACA business and overall company performance, especially with 2026 repricing and potential subsidy changes.

    And that really underscores why we're proactively leaning into disciplined '26 pricing, why we're intensifying the key management programs that are in flight, why we're looking at selective provider contract actions, again, to help rebuild margin and ensure long-term sustainability.

    Q&A highlights

    7

    Delineate pressure between unit cost trends and risk pool shifts in ACA; explain unchanged risk adjustment expectation despite higher morbidity.

    ACA pressure is 70% from risk pool acuity/morbidity (Medicaid migration, lower effectuation rates) and 30% from utilization (ER, behavioral health, specialty pharmacy) and aggressive coding/IDR misuse. Risk adjustment unchanged because morbidity is market-wide, not due to membership mix shift.

    “There are 3 principal factors that we are monitoring and which are behind the sharper uptick on medical trends in our ACA book. The first is the risk pool acuity and morbidity, which has risen materially as a result of the higher proportion of relatively healthier members, especially in states with a larger portion of fully subsidized individuals.”

    asked by Andrew Mok · answered by Mark Kaye

    2 min read7 chapters

    Detailed Narrative

    01

    Revised Full-Year Outlook and Strategic Response

    Elevance Health revised its FY25 adjusted EPS guidance to approximately $30, attributing the change to persistent elevated medical cost trends in ACA and slower Medicaid rate alignment. Management emphasized a prudent approach, not assuming a near-term recovery, and is focusing on execution, cost management, and targeted investments to strengthen the business. This decision aims to rebuild long-term margin stability and provide clear visibility to investors.

    02

    ACA Market Dynamics and Repricing

    The ACA market is undergoing a broad recalibration, with increased morbidity driven by membership shifts from Medicaid post-redetermination and lower effectuation rates. This has resulted in elevated medical cost trends, with risk pool acuity and morbidity accounting for approximately 70% of the total impact. The company's 2026 rate filings incorporate this higher market acuity and anticipate further risk pool deterioration if enhanced subsidies expire, leading to a potential 'last chance uptick' in Q4 utilization.

    03

    Medicaid Margin Recovery and State Engagement

    Medicaid cost trend deceleration was more modest than initially expected, primarily due to higher acuity from ongoing disenrollment and increased member utilization. While rate updates aligned with initial assumptions, they lagged current trend levels, leading to a prolonged margin recovery period. Elevance Health is proactively engaging with state partners, sharing data to support rate adjustments, and expects normalization over a couple of rate cycles, noting constructive discussions despite the lag.

    04

    Carelon Platform Growth and Performance

    The Carelon platform continues to be a strong growth engine for the company. Carelon Rx grew operating revenue by over 20% year-over-year, expanding its specialty pharmacy assets and gaining traction with larger clients, though profitability was impacted by growth initiatives. Carelon Services delivered over 50% growth in revenue and operating gain through expanded risk-based relationships and the integration of CareBridge, with margins performing within expectations.

    05

    Cost Management and Payment Integrity Initiatives

    Elevance Health is implementing structural cost levers, including streamlining prior authorization processes, with over 50% of electronic requests now processed in real-time. The company utilizes AI-enabled tools like Health OS and advanced analytics to identify fraud, waste, and abuse. Notably, a legal suit has been filed against the misuse of the Independent Dispute Resolution (IDR) process under the No Surprises Act, targeting inflated billing practices that can be as high as 21 times bill charges.

    06

    Medicare Advantage Discipline and Stability

    Medicare Advantage cost trends remained consistent with expectations, and Part D seasonality progressed as anticipated. For 2026, the company is maintaining a disciplined approach to bidding, focusing on margin normalization and sustainable long-term value. The strategy prioritizes HMO, duals, and margin-focused plan types, reflecting a multi-year effort to achieve stability in this market.

    07

    Commercial Business Performance

    The large group commercial business continues to demonstrate strong and consistent margin performance, which is expected to continue in 2025. The market is showing signs of hardening in terms of pricing, and the company has achieved good retention rates for its fully insured products. While some entities are moving to self-funded arrangements, these often remain within Elevance Health's portfolio.

    AI-generated summary of the company’s earnings call. Not investment advice.